SAB4700240
Monoclonal Anti-CD52 antibody produced in mouse
clone HI186, purified immunoglobulin, buffered aqueous solution
Synonym(e):
Anti-CAMPATH-1
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
UNSPSC-Code:
12352203
NACRES:
NA.41
Empfohlene Produkte
Biologische Quelle
mouse
Qualitätsniveau
Konjugat
unconjugated
Antikörperform
purified immunoglobulin
Antikörper-Produkttyp
primary antibodies
Klon
HI186, monoclonal
Form
buffered aqueous solution
Speziesreaktivität
human
Konzentration
1 mg/mL
Methode(n)
flow cytometry: suitable
Isotyp
IgG2b
NCBI-Hinterlegungsnummer
UniProt-Hinterlegungsnummer
Versandbedingung
wet ice
Lagertemp.
2-8°C
Posttranslationale Modifikation Target
unmodified
Angaben zum Gen
human ... CD52(1043)
Allgemeine Beschreibung
The antibody HI186 reacts with CD52 (CAMPATH-1), a 21-28 kDa glycoprotein containing a large N-linked carbohydrate moiety; mature CD52 molecule is actually much smaller (approx. 8-9 kDa). CD52 is expressed at high levels on lymphocytes, monocytes/macrophages and in male reproductive tract.
Immunogen
Human tonsil
Anwendung
The reagent is designed for Flow Cytometry analysis. Suggested working dilution for Flow Cytometry is 2 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Leistungsmerkmale und Vorteile
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physikalische Form
Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Sie haben nicht das passende Produkt gefunden?
Probieren Sie unser Produkt-Auswahlhilfe. aus.
Lagerklassenschlüssel
10 - Combustible liquids
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
T Nikolic et al.
Genes and immunity, 18(3), 176-183 (2017-08-11)
Tolerogenic dendritic cells (tolDCs) are assessed as immunomodulatory adjuvants to regulate autoimmunity. The underlying gene expression endorsing their regulatory features remains ill-defined. Using deep mRNA sequencing, we compared transcriptomes of 1,25-dihydroxyvitaminD
Sarah K Tasian et al.
Blood, 129(17), 2395-2407 (2017-03-02)
We and others previously reported potent antileukemia efficacy of CD123-redirected chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) models at the cost of severe hematologic toxicity. This observation raises concern for potential myeloablation in patients
Gaetano Lucisano et al.
Transplant international : official journal of the European Society for Organ Transplantation, 32(9), 949-959 (2019-04-14)
There are conflicting data about the role of transplant nephrectomy and immunosuppression withdrawal on the development of allosensitization and the impact on re-transplantation. We divided 109 first graft recipients into two groups according to whether they underwent nephrectomy (NX+, n = 61)
Jianhui Liu et al.
Biological & pharmaceutical bulletin, 41(9), 1423-1429 (2018-06-15)
Recent studies suggested that excessive T helper (Th)1/17 cells concomitant with regulatory T cell deficiency might play important roles in Crohn's disease. Anti-cluster of differentiation 52 (CD52) monoclonal antibody (mAb), which aims on CD52 antigen on mature immunocytes, has both
Carlos Cuesta-Mateos et al.
Biomarker research, 8, 54-54 (2020-10-29)
T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.